Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | DGKA | P23743 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | PAM | P19021 | 2/20 | 0.48 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6823809 | 1.00 | CYP1A2 (0.59) | CYP1A2DGKAALDH1A1ALOX15TDP1 | |
| SCHEMBL10534701 | 1.00 | CYP1A2 (0.59) | CYP1A2DGKAALDH1A1ALOX15TDP1 | |
| SCHEMBL28663838 | 1.00 | CYP1A2 (0.59) | CYP1A2DGKAALDH1A1ALOX15TDP1 | |
| SCHEMBL16022550 | 1.00 | CYP1A2 (0.59) | CYP1A2DGKAALDH1A1ALOX15TDP1 | |
| SCHEMBL8417337 | 0.98 | CYP1A2 (0.61) | CYP1A2DGKAALDH1A1ALOX15TDP1 | |
| Ethylene SCHEMBL11466234 | 0.96 | CYP1A2 (0.55) | CYP1A2DGKAALDH1A1ALOX15TDP1 | |
| 2-Nonanone SCHEMBL28983324 | 0.94 | DGKA (0.64) | CYP1A2DGKAALDH1A1TSHRPAM | |
| SCHEMBL723390 | 0.93 | CYP1A2 (0.61) | CYP1A2DGKAALDH1A1ALOX15TDP1 | |
| Ethane SCHEMBL11195854 | 0.91 | CYP1A2 (0.59) | CYP1A2DGKAALDH1A1ALOX15TDP1 | |
| SCHEMBL6055406 | 0.91 | CYP1A2 (0.70) | CYP1A2DGKAALDH1A1ALOX15TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1264836-B1 | Processes for the preparation of indolopyrrolocarbazole derivatives | BANYU PHARMA CO LTD (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | FISHER MATTHEW J (US) | 2003-07-10 | — | — | US | disclosed |
| EP-0804431-B9 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1264836-A1 | Processes for the preparation of indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-6448269-B1 | SUCH AS 6-(N-(4-(AMINOIMINOMETHYL)BENZOYL)AMINO)-3,4-DIHYDRO-4,4-DIMETHYL-2H-1 -BENZOPYRAN-2-YL)ACETIC ACID; INHIBITING PLATELET AGGREGATION OR FIBRINOGEN BINDING OR PREVENTING THROMBOSIS | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-0804431-B1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6020362-A | ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| US-5922860-A | Antitumor indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-5804564-A | Antitumor indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| EP-0804431-A4 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | LILLY CO ELI (US) | 1998-04-29 | — | — | EP | disclosed |
| US-5731324-A | Glycoprotein IIb/IIIa antagonists | ELI LILLY AND COMPANY (US) | 1998-03-24 | — | — | US | disclosed |
| EP-0804431-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-11-05 | — | — | EP | disclosed |
| EP-0760375-A1 | ANTITUMOR INDOLOPYPROLOCARBAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996022288-A1 | GLYCOPROTEIN IIb/IIIa ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-4997836-A | Inhibitor of platelet activating factor | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-03-05 | — | — | US | disclosed |
| EP-0368670-A1 | Trisubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1990-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130342-A1 | Glycoprotein llb/llla antagonists | SELL, SELPLG, LY96 | CYP1A2 3254/4885DGKA 2719/4885ALDH1A1 1693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.